Abstract

FORMULATION AND CHARACTERIZATION OF BRINZOLAMIDE NANOSTRUCTURED LIPID CARRIERS FOR OCCULAR DRUG DELIVERY

*Selvaraj S., Rajeshwari M. K. and Perumal P.

.

Abstract

Topical administration of ophthalmic drugs faces significant challenges, primarily associated with inadequate permeability and limited residence time in the eye. In an effort to overcome these issues, a formulation incorporating innovative lipidic nanoparticles with a specialized surface coating was developed. Brinzolamide, intended for the treatment of elevated intraocular pressure, faces challenges related to poor aqueous solubility and permeability. A formulation of Brinzolamide entrapped within mucoadhesive lipidic nanoparticles was developed, utilizing Glyceryl monostearate and Oleic acid as solid and liquid lipids, respectively, with Poloxamer 188 as the surfactant. The resultant Brinzolamide-loaded lipidic nanoparticles were further coated with chitosan hydrochloride to enhance mucoadhesion. Comprehensive evaluation of the optimized formulation included zeta potential, morphology and in vitro drug release. The surface-coated lipidic nanoparticles containing Brinzolamide exhibited a particle size of 125.13±12.454 nm, a PDI of 0.131±0.06, and %EE of 66.34±2.874%, with a positive zeta potential of 9.31±0.88 mV.

Keywords: Brinzolamide, Lipidic nanoparticles, Mucoadhesion, Chitosan hydrochloride, Poloxamer 188, Glyceryl monostearate, In vitro drug release.